Immunotherapy drug shows limited promise in tough bile duct cancer

NCT ID NCT02829918

Completed Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 54 patients with advanced biliary tract cancer that had stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors. While nivolumab is approved for other cancers, it is not yet approved for this type. The study measured how many patients responded after four cycles of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nivolumab (Opdivo), a cancer immunotherapy drug
What this could lead to: If successful, this could point toward a new treatment option for patients with advanced biliary tract cancer who have run out of standard therapies.
What could go wrong: This is a small, early-phase trial (54 patients) with no control group. The drug may not work for most patients, and side effects from immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer biliary tract neoplasm Biliary Tract Neoplasms Digestive System Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER BILIARY TRACT NEOPLASMS

Contacts and locations

Locations

City of Hope Cancer Center

Duarte, California, 91010, United States
Emory University Winship Cancer Institute

Atlanta, Georgia, 30322, United States
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.